What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
1. REGN stock is 44% below its 1-year peak. 2. Solid revenue growth of 5.4% LTM with good cash flow. 3. REGN's PE ratio is moderately low at 13.4. 4. The stock avoided significant margin shocks over the past year. 5. Historical declines indicate REGN is vulnerable during market disruptions.